FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290794147> ?p ?o ?g. }

• W4290794147 endingPage "506" @default.
• W4290794147 startingPage "503" @default.
• W4290794147 abstract "To the Editors Dissociative disorders (DDs) and dissociative states coexisting with other psychiatric disorders are highly prevalent in the psychiatric population and may be underdiagnosed. In an outpatient psychiatric population, the prevalence of DDs was 29%, and only 5% had previously received a DD diagnosis.1 Dissociative symptoms often coexist with depressive symptoms in patients with major depressive disorder (MDD),2 and there is a relationship between depression severity and dissociative symptoms in bulimic patients.3 Dissociative symptoms may precede the onset of mood disorders, could be a risk factor for their development, and may be added to those more traditionally considered as prodromal in depression.4–7 Uncompetitive N-methyl-d-aspartate receptor (NMDAR) channel blockers have been proposed as a treatment for posttraumatic stress disorder (PTSD). Ketamine, an NMDAR antagonist with antidepressant efficacy, has shown efficacy in PTSD.8 REL-1017 (esmethadone), the opioid-inactive (S)-enantiomer of methadone, is a novel, low potency NMDAR channel blocker,9 which currently is in phase 3 clinical trials for MDD. In phase 1 and phase 2 trials, REL-1017 showed very favorable safety, tolerability, and pharmacokinetic profiles and rapid, robust, and sustained antidepressant efficacy without clinically meaningful opioid-like effects or dissociative effects.10–12 We report 2 patients enrolled in a phase 2a trial11 experiencing a current major depressive episode and with clinically meaningful dissociative symptoms evaluated on the Clinician-Administered Dissociative States Scale (CADSS).13 Both patients had been diagnosed with MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria and had inadequate responses to 1 to 3 courses of antidepressant treatment as defined by the Antidepressant Treatment Response Questionnaire.14 They were admitted to a clinical research unit for approximately 10 days, where they received REL-1017 or placebo daily, for 7 consecutive days as adjunctive treatment for MDD. Both patients gave written informed consent to publish their cases. Case 1 A 31-year-old White male patient who had been diagnosed with MDD at age 18 years and who had a history of recurrent depressive episodes during his lifetime and no other psychiatric history was randomized to the REL-1017 25-mg subgroup in June 2019. In October 2018, he was first started on trazodone 300 mg, which was suspended after 3 months for lack of efficacy. At study entry, the patient had been taking bupropion 300 mg once daily for 11 months. On day 1 before and after the first dose of REL-1017, the total CADSS scores were 22 and 2, respectively, showing a clinically meaningful improvement in dissociative symptoms. This improvement was sustained on day 7 (2 hours after dose) with a CADSS total score of 6 and after treatment discontinuation, on day 9, with a complete resolution of symptoms (a CADSS total score of 0; Table 1). The baseline depressive symptoms total score, the Montgomery-Åsberg Depression Rating Scale (MADRS) was 18. On day 2 (before dose) and on day 4, the MADRS scores were 15 and 19, respectively. The measurement on day 7 was 17, and the value was not available at day 14 because the patient was lost to follow-up after discharge. The patient reported no adverse events except for mild constipation resolving spontaneously without any treatment. TABLE 1 - Clinician-Administered Dissociative States Scale Total Score and Item Scores for the 2 Patients at 4 Evaluation Time Points: Day 1 Predose, Day 1 Postdose, Day 7 Post–Last Dose, and Day 9 Patient 1(Assigned to REL-1017 25 mg, 75-mg Loading Dose on Day 1) Patient 2(Assigned to REL-1017 50 mg, 100-mg Loading Dose on Day 1) CADSS (total score) at each time point 22, 2, 6, 0 35, 14, 9, 0 Single itemDefinition and score for the 2 patients 1) Do things seem to be moving in slow motion? 2/0/0/0 3/1/1/0 2) Do things seem to be unreal, as if you are in a dream? 0/0/0/0 3/1/1/0 3) Do you have some experiences that separates you from what is happening; for instance, do you feel as you are in a movie or a play, or as if you are a robot? 0/0/0/0 3/1/0/0 4) Do you feel as if you are looking at things from outside of your body? 0/0/0/0 3/1/0/0 5) Do you feel as if you are watching the situation as an observer or spectator? 2/0/0/0 3/1/1/0 6) Do you feel disconnected from own body? 1/0/0/0 3/1/0/0 7) Does sense of your own body feel changed: for instance, does your own body feel changed unusually large or unusually small? 2/0/0/0 1/1/0/0 8) Do people seem motionless/dead or mechanical? 0/0/0/0 3/1/0/0 9) Do objects look different than you would expect? 0/0/0/0 1/0/0/0 10) Do colors seem to be diminished in intensity? 0/0/0/0 0/0/0/0 11) Do you see things as if you are in a tunnel, or looking through a wide-angle photographic lens? 0/0/0/0 2/0/0/0 12) Does this experience seem to take much longer than you would expected? 0/0/0/0 1/1/1/0 13) Do things seem to be happening very quickly, as if there is a lifetime in a moment? 0/0/1/0 0/0/0/0 14) Do things happen that you later cannot account for? 2/0/0/0 1/1/0/0 15) Do you space out, or in some other way lose track of what is going on? 0/0/0/0 1/1/1/0 16) Do sounds almost disappear or become much stronger than you would have expected? 0/0/0/0 0/0/1/0 17) Do things seem to be very real, as if there is a special sense of clarity? 3/0/2/0 0/0/1/0 18) Does it seem as if you are looking at the world through a fog, so that people and objects appear far away or unclear? 2/0/0/0 1/1/0/0 19) Do colors seem much brighter than you would have expected? 0/0/0/0 0/0/0/0 20) Do you feel confused about who you really are? 2/0/0/0 2/0/1/0 21) Do feel there are different parts of yourself, which do not fit together? 2/0/0/0 1/1/0/0 22) Do you have gaps in your memory? 3/2/3/0 2/1/1/0 23) Do you feel like you have more than one identity? 1/0/0/0 1/0/0/0 Case 2 A 39-year-old African American male patient first diagnosed with MDD at age 21 years was randomized to the REL-1017 50-mg subgroup. The patient had a history of recurrent depressive episodes during his lifetime and no other psychiatric history. In April 2018, he was started on sertraline 100 mg once a day orally, which was suspended in January 2019 because of lack of efficacy. At study entry, the patient had been taking bupropion 300 mg once daily for 6 months. On day 1 before the study drug administration and on day 1 after the first dose, the total CADSS scores reported by the patient were 35 and 14 showing a clinically meaningful improvement in dissociative symptoms. This improvement was sustained on day 7 (2 hours after dose) with a CADSS total score of 9, and after treatment discontinuation on day 9, with a complete resolution of symptoms (a CADSS total score of 0; Table 2). The baseline depressive symptoms total score evaluated on MADRS scale was 31. On day 2 (before dose) and on day 4, the total MADRS scores were 24 and 22, respectively. The measurements on day 7 and on day 14 were 24 and 23, respectively. The patient reported no adverse events except for a mild constipation spontaneously resolved without any treatment. These case reports suggest a potential therapeutic role for NMDAR uncompetitive antagonists in patients with overlapping symptomatology of depression and dissociation with poor response to standard antidepressant treatments. Different hypotheses have been proposed concerning the nature and role of dissociation in the context of MDD.2,15 Dissociative symptoms have been related to childhood trauma or traumatic adult life events and are considered risk factors for developing psychiatric disorders and an indicator of severity for MDD, as proposed by the depersonalization item in the Hamilton Rating Scale for Depression.2 Given the strong polygenic association of major depressive disorder and PTSD,16 an overlap in pharmacological treatments for these 2 conditions is conceivable. These preliminary data signal that REL-1017 may potentially determine rapid improvement in dissociative symptoms in patients with MDD experiencing dissociative symptoms with a temporal association to acute changes in mood, which needs further investigations. These preliminary results need to be replicated in larger and longer trials. Ongoing phase 3 clinical trials with REL-1017 could generate additional data supporting the initiation of future clinical studies on REL-1017 for the treatment of PTSD. Clotilde Guidetti, MDGiulia Serra, MD Child and Adolescent Neuropsychiatry Unit Department of Neurological and Psychiatric Science Bambino Gesù Children’s Hospital Rome, ItalyLuca Pani, MD Department of Psychiatry and Behavioral Sciences University of Miami School of Medicine Miami, FL Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia, ItalyMarco Pappagallo, MD Relmada Therapeutics Coral Gables FL Department of Anesthesiology Albert Einstein College of Medicine Bronx, NYGino Maglio, MDMonia Trasolini, MD Child and Adolescent Neuropsychiatry Unit Department of Neurological and Psychiatric Science Bambino Gesù Children’s Hospital Rome, ItalySara De Martin, PhDAndrea Mattarei, PhD Department of Pharmaceutical and Pharmacological Sciences University of Padova Padova, ItalyFrancesco Bifari, MD, PhD Department of Medical Biotechnology and Translational Medicine University of Milan Milan, ItalyFranco Folli, MD, PhD Department of Health Science University of Milano Milan, ItalyPaolo L. Manfredi, MD Relmada Therapeutics Coral Gables, FL [email protected]Maurizio Fava, MD Department of Psychiatry Massachusetts General Hospital Boston, MA" @default.
• W4290794147 created "2022-08-09" @default.
• W4290794147 creator A5001997577 @default.
• W4290794147 creator A5004302186 @default.
• W4290794147 creator A5014569398 @default.
• W4290794147 creator A5016785133 @default.
• W4290794147 creator A5024208748 @default.
• W4290794147 creator A5025926000 @default.
• W4290794147 creator A5053802958 @default.
• W4290794147 creator A5059921142 @default.
• W4290794147 creator A5065191888 @default.
• W4290794147 creator A5065244580 @default.
• W4290794147 creator A5082029300 @default.
• W4290794147 creator A5084024326 @default.
• W4290794147 date "2022-08-06" @default.
• W4290794147 modified "2023-09-30" @default.
• W4290794147 title "REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants" @default.
• W4290794147 cites W1569013600 @default.
• W4290794147 cites W2002489043 @default.
• W4290794147 cites W2044031389 @default.
• W4290794147 cites W2070392816 @default.
• W4290794147 cites W2087482773 @default.
• W4290794147 cites W2087912588 @default.
• W4290794147 cites W2094957254 @default.
• W4290794147 cites W2097857685 @default.
• W4290794147 cites W2740844751 @default.
• W4290794147 cites W2885169221 @default.
• W4290794147 cites W2925451033 @default.
• W4290794147 cites W3120445729 @default.
• W4290794147 cites W3125060799 @default.
• W4290794147 cites W3192434366 @default.
• W4290794147 cites W4200195182 @default.
• W4290794147 cites W4238443135 @default.
• W4290794147 doi "https://doi.org/10.1097/jcp.0000000000001583" @default.
• W4290794147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35943402" @default.
• W4290794147 hasPublicationYear "2022" @default.
• W4290794147 type Work @default.
• W4290794147 citedByCount "2" @default.
• W4290794147 countsByYear W42907941472022 @default.
• W4290794147 countsByYear W42907941472023 @default.
• W4290794147 crossrefType "journal-article" @default.
• W4290794147 hasAuthorship W4290794147A5001997577 @default.
• W4290794147 hasAuthorship W4290794147A5004302186 @default.
• W4290794147 hasAuthorship W4290794147A5014569398 @default.
• W4290794147 hasAuthorship W4290794147A5016785133 @default.
• W4290794147 hasAuthorship W4290794147A5024208748 @default.
• W4290794147 hasAuthorship W4290794147A5025926000 @default.
• W4290794147 hasAuthorship W4290794147A5053802958 @default.
• W4290794147 hasAuthorship W4290794147A5059921142 @default.
• W4290794147 hasAuthorship W4290794147A5065191888 @default.
• W4290794147 hasAuthorship W4290794147A5065244580 @default.
• W4290794147 hasAuthorship W4290794147A5082029300 @default.
• W4290794147 hasAuthorship W4290794147A5084024326 @default.
• W4290794147 hasBestOaLocation W42907941471 @default.
• W4290794147 hasConcept C118552586 @default.
• W4290794147 hasConcept C15744967 @default.
• W4290794147 hasConcept C169900460 @default.
• W4290794147 hasConcept C2778807096 @default.
• W4290794147 hasConcept C3019858935 @default.
• W4290794147 hasConcept C70410870 @default.
• W4290794147 hasConcept C71924100 @default.
• W4290794147 hasConceptScore W4290794147C118552586 @default.
• W4290794147 hasConceptScore W4290794147C15744967 @default.
• W4290794147 hasConceptScore W4290794147C169900460 @default.
• W4290794147 hasConceptScore W4290794147C2778807096 @default.
• W4290794147 hasConceptScore W4290794147C3019858935 @default.
• W4290794147 hasConceptScore W4290794147C70410870 @default.
• W4290794147 hasConceptScore W4290794147C71924100 @default.
• W4290794147 hasIssue "5" @default.
• W4290794147 hasLocation W42907941471 @default.
• W4290794147 hasLocation W42907941472 @default.
• W4290794147 hasLocation W42907941473 @default.
• W4290794147 hasLocation W42907941474 @default.
• W4290794147 hasLocation W42907941475 @default.
• W4290794147 hasLocation W42907941476 @default.
• W4290794147 hasOpenAccess W4290794147 @default.
• W4290794147 hasPrimaryLocation W42907941471 @default.
• W4290794147 hasRelatedWork W2056362975 @default.
• W4290794147 hasRelatedWork W2069410535 @default.
• W4290794147 hasRelatedWork W2105099517 @default.
• W4290794147 hasRelatedWork W2132310355 @default.
• W4290794147 hasRelatedWork W2169153717 @default.
• W4290794147 hasRelatedWork W2169895294 @default.
• W4290794147 hasRelatedWork W2558221300 @default.
• W4290794147 hasRelatedWork W2748952813 @default.
• W4290794147 hasRelatedWork W2793075332 @default.
• W4290794147 hasRelatedWork W2899084033 @default.
• W4290794147 hasVolume "42" @default.
• W4290794147 isParatext "false" @default.
• W4290794147 isRetracted "false" @default.
• W4290794147 workType "article" @default.